ImmuPharma plc (LON:IMM – Get Free Report) shares traded down 15.6% during trading on Thursday . The company traded as low as GBX 4.60 ($0.06) and last traded at GBX 4.98 ($0.06). 68,204,375 shares changed hands during trading, an increase of 164% from the average session volume of 25,820,418 shares. The stock had previously closed at GBX 5.90 ($0.07).
ImmuPharma Stock Performance
The stock has a fifty day simple moving average of GBX 2.14 and a two-hundred day simple moving average of GBX 1.85. The stock has a market capitalization of £21.65 million, a price-to-earnings ratio of -520.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- Expert Stock Trading Psychology Tips
- Nebius Group: Market Overreaction or Real AI Disruption?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- The Best Way to Invest in Gold Is…
- Growth Stocks: What They Are, Examples and How to Invest
- Why Nike Stock Could Be 2025’s Top Comeback Play
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
